Literature DB >> 18456872

Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil.

Takahiro Nagayama1, Manling Zhang, Steven Hsu, Eiki Takimoto, David A Kass.   

Abstract

Phosphodiesterase type 5 (PDE5) inhibitors are used to treat erectile dysfunction, and growing evidence supports potential cardiovascular utility. Their efficacy declines with reduced nitric-oxide synthase (NOS) activity common to various diseases. We tested whether direct soluble guanylate cyclase (sGC) stimulation restores in vivo cardiovascular modulation by PDE5 inhibition despite acute or chronically suppressed NOS activity. Mice (C57/Bl6; n = 62) were studied by in vivo pressure-volume analysis to assess acute modulation by the PDE5 inhibitor sildenafil (SIL; 100 microg/kg/min) of the cardiac response to isoproterenol (ISO) with or without NOS inhibition [N(omega)-nitro-L-arginine methyl ester (L-NAME)] and cotreatment by the sGC stimulator 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)pyrimidine-4,6-diamine (BAY 41-8543). SIL induced mild vasodilation but no basal cardiac effects and markedly blunted ISO-stimulated contractility. Acute BAY 41-8543 at a dose lacking cardiovascular effects did not alter ISO responses. However, after acute L-NAME, SIL ceased to influence cardiovascular function, but adding BAY 41-8543 fully restored SIL effects. After 1 week of L-NAME, neither SIL nor SIL + BAY 41-8543 acutely induced vasodilation or blunted ISO responses. However, sustained BAY 41-8543 despite concurrent NOS inhibition restored the cardiovascular efficacy of SIL. The disparity between acute and chronic NOS inhibition related to diffusion of PDE5 away from myocyte z-bands coupled with reduced protein kinase G activation. Both were restored by sustained sGC costimulation. Thus, PDE5 regulation of adrenergic reserve and systemic vasodilation depends upon NOS-induced cGMP/protein kinase G and can be enhanced by sustained low-level stimulation of sGC. This may prove beneficial for enhancing the efficacy of PDE5 inhibitors in conditions with chronically reduced NOS activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456872     DOI: 10.1124/jpet.108.137422

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  Systems biology and heart failure: concepts, methods, and potential research applications.

Authors:  Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

Review 3.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

Review 4.  Emerging drugs for Duchenne muscular dystrophy.

Authors:  Vinod Malik; Louise R Rodino-Klapac; Jerry R Mendell
Journal:  Expert Opin Emerg Drugs       Date:  2012-06       Impact factor: 4.191

5.  Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy.

Authors:  Justin M Percival; Candace M Adamo; Joseph A Beavo; Stanley C Froehner
Journal:  Handb Exp Pharmacol       Date:  2011

6.  Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction.

Authors:  U Ozturk; S Yesil; H N G Goktug; A Gucuk; C Tuygun; N C Sener; I Nalbant; M A Imamoglu
Journal:  Ir J Med Sci       Date:  2013-11-05       Impact factor: 1.568

Review 7.  Compartmentalization of cyclic nucleotide signaling: a question of when, where, and why?

Authors:  Kavisha Arora; Chandrima Sinha; Weiqiang Zhang; Aixia Ren; Chang Suk Moon; Sunitha Yarlagadda; Anjaparavanda P Naren
Journal:  Pflugers Arch       Date:  2013-04-19       Impact factor: 3.657

8.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

Authors:  Manling Zhang; Norimichi Koitabashi; Takahiro Nagayama; Ryan Rambaran; Ning Feng; Eiki Takimoto; Trisha Koenke; Brian O'Rourke; Hunter C Champion; Michael T Crow; David A Kass
Journal:  Cell Signal       Date:  2008-08-26       Impact factor: 4.315

Review 9.  Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications.

Authors:  Praneet Kumar; Gary S Francis; W H Wilson Tang
Journal:  Nat Rev Cardiol       Date:  2009-05       Impact factor: 32.419

10.  Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes.

Authors:  Honglan Wang; Mark J Kohr; Christopher J Traynham; Mark T Ziolo
Journal:  J Mol Cell Cardiol       Date:  2009-04-01       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.